Q1 EPS Estimates for Haemonetics Cut by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Stock analysts at Zacks Research lowered their Q1 2027 earnings per share (EPS) estimates for Haemonetics in a research note issued to investors on Tuesday, February 24th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.19 for the quarter, down from their prior estimate of $1.20. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q1 2028 earnings at $1.35 EPS and FY2028 earnings at $5.73 EPS.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the prior year, the business earned $1.19 earnings per share. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

A number of other equities research analysts have also recently commented on HAE. Barrington Research set a $94.00 price target on shares of Haemonetics in a report on Friday, February 6th. BTIG Research reissued a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Mizuho dropped their price target on Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research report on Friday, February 6th. Citigroup decreased their price objective on Haemonetics from $88.00 to $75.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $84.44.

Haemonetics Stock Down 0.2%

HAE opened at $62.21 on Thursday. Haemonetics has a twelve month low of $47.31 and a twelve month high of $87.32. The company’s 50-day moving average price is $70.47 and its two-hundred day moving average price is $63.96. The stock has a market cap of $2.89 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 1.30 and a beta of 0.28. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01.

Institutional Trading of Haemonetics

Institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. lifted its stake in Haemonetics by 1,405.7% in the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock worth $2,247,000 after purchasing an additional 43,042 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Haemonetics by 49.7% in the third quarter. Harbor Capital Advisors Inc. now owns 42,859 shares of the medical instruments supplier’s stock worth $2,089,000 after purchasing an additional 14,226 shares during the period. Boston Partners raised its position in shares of Haemonetics by 2.2% in the second quarter. Boston Partners now owns 543,169 shares of the medical instruments supplier’s stock worth $40,660,000 after buying an additional 11,738 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its stake in Haemonetics by 36.2% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock valued at $34,426,000 after buying an additional 187,630 shares during the period. Finally, Isthmus Partners LLC grew its position in Haemonetics by 36.5% during the third quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock worth $3,007,000 after buying an additional 16,505 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Key Headlines Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks nudged FY2026 EPS slightly higher to $4.95 (from $4.93), and raised its Q2 2027 estimate to $1.37 (from $1.35) — small upside near‑term beats that may cushion downside from other cuts. Zacks estimate updates (Feb 24)
• Neutral Sentiment: Zacks published a comprehensive set of updated quarterly and fiscal estimates (Q4 2026 – Q3 2028 and FY2026–FY2028), providing a refreshed model investors can use to re‑rate the stock. Zacks estimate updates (Feb 24)
• Negative Sentiment: Material downward revisions to the medium/longer term: Zacks cut FY2028 EPS to $5.73 from $5.90 and trimmed FY2027 to $5.34 from $5.37 — signaling lower expected growth beyond FY2026. Zacks estimate updates (Feb 24)
• Negative Sentiment: Zacks lowered multiple quarterly forecasts across 2026–2028 (examples: Q1 2028 to $1.35 from $1.39; Q1 2027 to $1.19 from $1.20; Q3 2028 to $1.51 from $1.53; Q2 2028 to $1.46 from $1.50; Q4 2027 and Q4 2026 also trimmed). These repeated downgrades put near‑term EPS risk on the table. Zacks estimate updates (Feb 24–25)

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.